Tumor Prevention and Genetics

  • Hans-Jörg Senn
  • Rudolf Morant
Conference proceedings

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 163)

Table of contents

  1. Front Matter
    Pages I-VII
  2. Introduction

    1. Hans-Jörg Senn
      Pages 1-3
  3. Latest News in Cancer Genetics

    1. Front Matter
      Pages 5-5
    2. John P. de Koning, Jian-Hua Mao, Allan Balmain
      Pages 19-27
  4. Assessing New Cancer Susceptibility Genes

    1. Front Matter
      Pages 29-29
    2. Friedrich Marks, Gerhard Fürstenberger, Gitta Neufang, Karin Müller-Decker
      Pages 46-57
    3. Eugene W. Gerner, Natalia A. Ignatenko, David G. Besselsen
      Pages 58-71
    4. Mukesh Verma, Sudhir Srivastava
      Pages 72-84
  5. Update in Chemoprevention of Breast Cancer

  6. Secondary Prevention of Breast Cancer: The Mammography Controversy

  7. Chemoprevention of Skin and Lung Cancer

    1. Front Matter
      Pages 149-149
    2. Janine G. Einspahr, G. Timothy Bowden, David S. Alberts
      Pages 151-164
    3. Kenneth G. Linden, Philip M. Carpenter, Christine E. McLaren, Ronald J. Barr, Pamela Rite, Joannie D. Sun et al.
      Pages 165-171
    4. Eva Szabo, Thea Kalebic
      Pages 172-181
    5. Stephen Lam, Calum MacAulay, Jean C. LeRiche, Adi F. Gazdar
      Pages 182-195
  8. Prevention and Screening of Prostate Cancer

    1. Front Matter
      Pages 197-197
    2. Claude C. Schulman, Alexandre R. Zlotta
      Pages 199-211
    3. Hans-Peter Schmid, Ladislav Prikler, Axel Semjonow
      Pages 226-231
  9. Prevention and Screening of Colorectal Cancer

    1. Front Matter
      Pages 233-233
    2. Hansjakob Müller, Martina Plasilova, Anna Marie Russell, Karl Heinimann
      Pages 235-247
    3. Philippe Autier, Peter Boyle, Marc Buyse, Harry Bleiberg
      Pages 254-263
    4. Rudolf Morant
      Pages 264-266

About these proceedings


Hans-Jorg Senn H.-J. Senn (~) Center for Tumor Detection and Prevention, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland Clinical oncology has centered mainly on developing new strategies and a multitude of new drugs for fighting relapsing and progressive cancer during the last two decades. Furthermore, it has done this with respectable success in quite a number of neoplastic diseases such as acute leukemias and sarcomas in pediatric patients and certain types of aggressive lymphomas, as well as se­ lected solid tumors such as testicular cancer and choriocarcinoma in adult age. Curatively intended adjuvant chemo-and endocrine-therapies of several "main killers" among prevalent cancer types, especially breast and colon can­ cer, have also become successful and health-politically meaningful therapeutic targets [1, 2]. However, the net gain in "cure" of these (mostly pharmacologic) therapeu­ tic approaches has to be realistically judged as having a moderate impact on the cancer problem as a whole, and the mortality rate of the most frequent tu­ mor types, which are prevalent in adult life, has with very few exceptions not been substantially decreased over the past two to three decades. Increasingly, health politicians, epidemiologists, and medical journal editors are asking for alternative strategies of lowering cancer incidence and increasing survival, ventilating new and hitherto mostly neglected areas of research such as pri­ mary and secondary cancer prevention.


Cancer Screening Cancer prevention breast cancer cancer genetics cancer screnning chemoprevention genes genetics

Editors and affiliations

  • Hans-Jörg Senn
    • 1
  • Rudolf Morant
    • 1
  1. 1.Zentrum für Tumordiagnostik und PräventionSt. GallenSwitzerland

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2003
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-62892-4
  • Online ISBN 978-3-642-55647-0
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods